A Novel Visual Model for Predicting Prognosis of Resected Hepatoblastoma: A Multicenter Study.
Objective: This study aimed to evaluate the application of a contrast-enhanced CT-based visual model in predicting postoperative prognosis in patients with hepatoblastoma (HB).
Methods: We analyzed data from 224 patients across three centers (178 in the training cohort, 46 in the validation cohort). Visual features were extracted from contrast-enhanced CT images, and key features, along with clinicopathological data, were identified using LASSO Cox regression. Visual (DINOv2_score) and clinical (Clinical_score) models were developed, and a combined model integrating DINOv2_score and clinical risk factors was constructed. Nomograms were created for personalized risk assessment, with calibration curves and decision curve analysis (DCA) used to evaluate model performance.
Results: The DINOv2_score was recognized as a key prognostic indicator for HB. In both the training and validation cohorts, the combined model demonstrated superior performance in predicting disease-free survival (DFS) [C-index (95% CI): 0.886 (0.879-0.895) and 0.873 (0.837-0.909), respectively] and overall survival (OS) [C-index (95% CI): 0.887 (0.877-0.897) and 0.882 (0.858-0.906), respectively]. Calibration curves showed strong alignment between predicted and observed outcomes, while DCA demonstrated that the combined model provided greater clinical net benefit than the clinical or visual models alone across a range of threshold probabilities.
Conclusions: The contrast-enhanced CT-based visual model serves as an effective tool for predicting postoperative prognosis in HB patients. The combined model, integrating the DINOv2_score and clinical risk factors, demonstrated superior performance in survival prediction, offering more precise guidance for personalized treatment strategies.